Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial | BMC Cancer | Full Text

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial | BMC Cancer | Full Text

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

There is no consensus on the therapeutic approach to ECOG 2 patients with locally advanced non-small-cell lung cancer (LA-NSCLC), despite the sizable percentage of these patients in clinical practice. This stu...

Authors:Nan Bi, Lipin Liu, Jun Liang, Shixiu Wu, Ming Chen, Changxing Lv, Lujun Zhao, Anhui Shi, Wei Jiang, Yaping Xu, Zongmei Zhou, Jingbo Wang, Wenqing Wang, Dongfu Chen, Zhouguang Hui, Jima Lv…

Citation:BMC Cancer 2020 20:278

Content type:Research article

Published on: 6 April 2020

• ViewFull Text
 
• ViewPDF